GO:0046469 platelet activating factor metabolic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046469 describes the chemical reactions and pathways involving platelet activating factor (PAF), a potent inflammatory phospholipid mediator.
• PAF is synthesized through remodeling and de novo pathways and is inactivated primarily by PAF acetylhydrolases (PAF-AHs), which remove the sn-2 acetyl group.
• PAF signals through a G-protein-coupled receptor to trigger platelet aggregation, leukocyte activation, and vascular permeability.
• Dysregulated PAF metabolism is implicated in atherosclerosis, cancer, neurodegeneration, and radiation-induced inflammation.
• Key enzymes include PLA2G7 (Lp-PLA2), PAFAH1B1, PAFAH1B2, PAFAH1B3, and LPCAT1/2, with additional roles for PLA2G4A and PTGS1 in precursor supply.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of PAF metabolic genes in disease contexts.
Description
Platelet activating factor (PAF) is a phospholipid mediator with the structure 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine, where the alkyl chain is typically hexadecyl or octadecyl. The Gene Ontology term GO:0046469, platelet activating factor metabolic process, encompasses the enzymatic reactions that synthesize, remodel, and degrade PAF, thereby controlling its local concentration and biological activity. PAF is released from a variety of cells in response to diverse stimuli and acts as a potent inflammatory mediator. Because PAF is not stored in large amounts but is generated on demand, its metabolic enzymes are central to regulating its signaling duration and intensity. Researchers study GO:0046469 to understand how lipid mediator balance contributes to thrombosis, allergy, cancer, and neurodegeneration. The pathway includes acetyltransferases, phospholipases, acetylhydrolases, and transacylases that together determine PAF half-life and receptor availability. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of PAF metabolism, its genes, disease links, and CRISPR-based experimental strategies.
platelet activating factor metabolic process At A Glance
| GO ID | GO:0046469 |
|---|---|
| GO term | platelet activating factor metabolic process |
| Ontology | biological_process |
| Synonym | PAF metabolic process; PAF metabolism; platelet activating factor metabolism |
| Definition | The chemical reactions and pathways involving platelet activating factor, 1-O-alkyl-2-acetyl-sn-glycerol 3-phosphocholine, where alkyl = hexadecyl or octadecyl. Platelet activating factor is an inflammatory mediator released from a variety of cells in response to various stimuli. |
| Major function | Synthesis, remodeling, and degradation of PAF to control its concentration and signaling duration. |
| Key enzymes | PAF acetylhydrolases (PLA2G7, PAFAH1B1, PAFAH1B2, PAFAH1B3), acetyltransferases (LPCAT1/2), phospholipases (PLA2G4A), and transacylases. |
| Subcellular location | Membrane-associated and secreted enzymes; PAF acts at the plasma membrane via its receptor. |
| Disease relevance | Atherosclerosis, cancer, neurodegeneration, and radiation-induced inflammation. |
What Is GO:0046469?
GO:0046469 (platelet activating factor metabolic process) is defined by QuickGO as the chemical reactions and pathways involving platelet activating factor, 1-O-alkyl-2-acetyl-sn-glycerol 3-phosphocholine, where alkyl = hexadecyl or octadecyl. PAF is an inflammatory mediator released from a variety of cells in response to various stimuli. In practice, this term covers the biosynthesis of PAF via remodeling and de novo routes, its extracellular and intracellular transport, and its inactivation by acetylhydrolases and transacylases.
Why Is platelet activating factor metabolic process Important in Cell Biology?
PAF is one of the most potent lipid mediators of inflammation, and its metabolic process determines whether PAF signals transiently or persistently. Because PAF is synthesized on demand and rapidly degraded, the enzymes of GO:0046469 act as a rheostat for inflammatory and thrombotic responses. Dysregulation of PAF metabolism has been linked to atherosclerosis, cancer progression, neurodegeneration, and radiation-induced tissue injury, making these enzymes attractive targets for therapeutic intervention and biomarker development.
• PAF is a key mediator of platelet aggregation and leukocyte activation.
• PAF acetylhydrolases control the half-life of PAF and thus the duration of inflammatory signaling.
• PAF-like oxidized phospholipids contribute to atherosclerosis and are metabolized by related enzymes.
• Radiation therapy generates PAF agonists that can promote tumor and stromal responses.
• Amyloid toxicity involves PAF signaling, linking lipid metabolism to neurodegeneration.
• PAF metabolic enzymes are potential drug targets for anti-inflammatory and anticancer therapies.
• Genetic variation in PAF-metabolizing enzymes may affect disease susceptibility.
• PAF metabolism intersects with eicosanoid and phospholipid pathways, influencing broader lipid mediator networks.
• Metabolic conversion of PAF into ethanolamine plasmalogen highlights its role in membrane lipid remodeling.
• CRISPR screens can identify novel regulators of PAF metabolism and signaling.
What Happens During platelet activating factor metabolic process?
PAF biosynthesis via the remodeling pathway
In simple terms: Cells quickly modify an existing membrane lipid to make PAF when stimulated.
The remodeling pathway is the major route for PAF synthesis in inflammatory cells. A phospholipase A2, such as PLA2G4A, hydrolyzes 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine to lyso-PAF, which is then acetylated by an acetyltransferase (e.g., LPCAT1 or LPCAT2) using acetyl-CoA to form PAF. This two-step process allows rapid PAF production upon cell activation without de novo synthesis of the entire phospholipid backbone.
PAF biosynthesis via the de novo pathway
In simple terms: Cells can also build PAF from simpler precursors through a longer series of enzymatic steps.
The de novo pathway starts from 1-O-alkyl-2-acetyl-sn-glycerol and proceeds through cholinephosphotransferase to yield PAF. This route is constitutively active in some tissues and contributes to basal PAF levels. The de novo pathway is particularly relevant in the kidney and other organs where PAF has homeostatic functions.
PAF degradation by acetylhydrolases
In simple terms: Enzymes remove the acetyl group from PAF, turning it into an inactive lipid.
PAF acetylhydrolases (PAF-AHs) hydrolyze the sn-2 acetyl group of PAF, producing lyso-PAF and acetate, which terminates PAF signaling. Plasma PAF-AH (PLA2G7, also known as lipoprotein-associated phospholipase A2) is secreted and associates with lipoproteins, while intracellular PAF-AH Ib consists of catalytic subunits PAFAH1B2 and PAFAH1B3 and a regulatory subunit PAFAH1B1 (LIS1). These enzymes are critical for controlling PAF half-life in circulation and tissues.
PAF transacylation and conversion to plasmalogens
In simple terms: PAF can be converted into other membrane lipids, recycling its backbone.
PAF can be metabolized by transacylation reactions that transfer an acyl chain to lyso-PAF or convert PAF into ethanolamine plasmalogen, as demonstrated in amnion-derived cells. This metabolic conversion links PAF turnover to membrane phospholipid remodeling and may serve as a detoxification route.
PAF signaling and receptor-mediated effects
In simple terms: PAF binds to its receptor on target cells to trigger inflammatory responses.
PAF exerts its biological effects by binding to the PAF receptor (PTAFR), a G-protein-coupled receptor that activates phospholipase C, MAP kinases, and NF-kB pathways. This signaling leads to platelet aggregation, leukocyte chemotaxis, and increased vascular permeability. The metabolic process regulates the amount of PAF available to activate PTAFR, thereby modulating these responses.
Key Genes Involved in GO:0046469 platelet activating factor metabolic process
The following genes encode enzymes and proteins directly involved in PAF metabolism, including biosynthesis, degradation, and signaling.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PLA2G7 | Plasma PAF acetylhydrolase; hydrolyzes PAF and oxidized phospholipids | Biomarker for cardiovascular risk; target for anti-inflammatory therapy |
| PAFAH1B1 | Regulatory subunit of intracellular PAF acetylhydrolase Ib (LIS1) | Mutations cause lissencephaly; role in neuronal migration |
| PAFAH1B2 | Catalytic subunit of PAF acetylhydrolase Ib | Enzyme activity in brain and other tissues |
| PAFAH1B3 | Catalytic subunit of PAF acetylhydrolase Ib | Enzyme activity; potential tumor suppressor context |
| LPCAT1 | Lysophosphatidylcholine acyltransferase 1; acetyltransferase for PAF synthesis | Remodeling pathway enzyme; cancer and inflammation |
| LPCAT2 | Lysophosphatidylcholine acyltransferase 2; acetyltransferase for PAF synthesis | Inducible PAF synthesis in macrophages |
| PLA2G4A | Cytosolic phospholipase A2; generates lyso-PAF precursor | Inflammatory signaling; eicosanoid and PAF production |
| PTAFR | PAF receptor; mediates PAF signaling | Drug target for allergy and inflammation |
| PLA2G2A | Secretory phospholipase A2; may contribute to lyso-PAF formation | Inflammatory diseases; antibacterial roles |
| PLA2G5 | Secretory phospholipase A2; implicated in PAF synthesis | Asthma and cardiovascular biology |
| CHPT1 | Cholinephosphotransferase 1; de novo PAF synthesis | Constitutive PAF production |
| CEPT1 | Choline/ethanolamine phosphotransferase 1; de novo pathway | Membrane lipid synthesis |
| PLAAT3 | Phospholipase A and acyltransferase 3; transacylation | PAF remodeling and detoxification |
| LYPLA1 | Lysophospholipase 1; may hydrolyze PAF | Lipid mediator turnover |
| LYPLA2 | Lysophospholipase 2; may hydrolyze PAF | Lipid mediator turnover |
| PLA2G10 | Secretory phospholipase A2; potential lyso-PAF generator | Inflammation and host defense |
| PLA2G4E | Cytosolic phospholipase A2 epsilon; PAF-related lipid metabolism | Epidermal and inflammatory biology |
| PAFAH2 | PAF acetylhydrolase 2; intracellular PAF-AH | Oxidative stress and detoxification |
How Is platelet activating factor metabolic process Regulated?
PAF metabolism is regulated at multiple levels. Transcriptional induction of LPCAT2 and PLA2G4A occurs in response to inflammatory stimuli, increasing PAF synthesis. Conversely, PAF acetylhydrolase activity can be regulated by secretion and association with lipoproteins, affecting PAF half-life in plasma. Calcium-dependent translocation of cytosolic phospholipase A2 to membranes is a key control point for lyso-PAF generation. Additionally, oxidative stress can generate PAF-like oxidized phospholipids that are substrates for PAF-AH, linking redox status to PAF metabolism. The balance between biosynthetic and degradative enzymes ultimately determines PAF bioavailability and signaling duration.
platelet activating factor metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PLA2G7 | Atherosclerosis; cardiovascular risk biomarker | Knockout and overexpression in macrophages and endothelial cells |
| PAFAH1B1 | Lissencephaly; neuronal migration disorder | Knockout and point-mutation in neuronal stem cells and mouse models |
| PTAFR | Allergy; asthma; anaphylaxis | Knockout and point-mutation in mast cells and airway epithelium |
| LPCAT2 | Inflammatory macrophage activation | Knockout and overexpression in macrophage cell lines |
| PLA2G4A | Inflammatory diseases; cancer | Knockout and point-mutation in cancer cell lines |
PAF metabolism in atherosclerosis and cardiovascular disease
PAF and PAF-like oxidized phospholipids promote endothelial dysfunction, monocyte recruitment, and foam cell formation, contributing to atherosclerosis. Plasma PAF-AH (PLA2G7) is a recognized biomarker for cardiovascular risk, and its ability to degrade oxidized phospholipids links PAF metabolism to plaque stability. Targeting PAF metabolic enzymes may reduce vascular inflammation.
PAF metabolism in cancer and radiation response
Radiation therapy generates PAF agonists that can promote tumor cell survival and inflammatory responses in the tumor microenvironment. PAF signaling through PTAFR has been implicated in cancer cell proliferation and metastasis. Inhibiting PAF metabolism or signaling may enhance the efficacy of radiotherapy and reduce treatment-related inflammation.
PAF metabolism in neurodegeneration
Amyloid toxicity involves PAF signaling, and PAF acetylhydrolase enzymes are expressed in the brain. Mutations in PAFAH1B1 cause lissencephaly, highlighting the importance of PAF metabolism in neuronal migration and brain development. PAF-mediated neuroinflammation may contribute to Alzheimer's disease and other neurodegenerative conditions.
PAF metabolism in inflammatory and allergic diseases
PAF is a potent mediator of allergic inflammation, asthma, and anaphylaxis. PAF receptor antagonists have been explored for asthma and allergic rhinitis, though clinical results have been mixed. Regulating PAF metabolism through acetylhydrolases could provide an alternative strategy to control PAF-driven inflammation.
From platelet activating factor metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PLA2G7 alter PAF degradation and atherosclerosis? | PLA2G7 knockout in macrophages and ApoE-/- mice |
| How does PAFAH1B1 mutation affect neuronal migration? | PAFAH1B1 point-mutation knock-in in neuronal stem cells |
| Does LPCAT2 overexpression increase PAF synthesis? | LPCAT2 overexpression in macrophage cell lines |
| Can tagged PAF-AH track subcellular localization? | Tagged knock-in of PAFAH1B2 or PAFAH1B3 |
| Does PTAFR knockout block PAF-induced signaling? | PTAFR knockout in mast cells or platelets |
| Which genes regulate PAF metabolism in cancer? | CRISPR library screening in cancer cell lines |
How to Study the platelet activating factor metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS lipidomics | PAF and related phospholipid species | Quantify PAF levels in cells and tissues |
| PAF-AH activity assay | Enzymatic hydrolysis of PAF | Validate knockout or point-mutation effects |
| CRISPR knockout screening | Gene essentiality for PAF metabolism | Identify novel regulators |
| RNA-seq | Transcriptional changes in PAF pathway genes | Inflammatory or radiation response |
| Proteomics | Protein expression and modifications | Characterize PAF enzyme complexes |
| Calcium flux assay | PAF receptor activation | Measure PAF signaling in live cells |
| Platelet aggregation assay | Functional PAF bioactivity | Assess PAF metabolism impact on thrombosis |
| Immunofluorescence | Subcellular localization of PAF enzymes | Track tagged knock-in proteins |
Lipidomics and mass spectrometry for PAF quantification
Mass spectrometry-based lipidomics enables sensitive detection and quantification of PAF and its precursors in biological samples. This method can distinguish PAF species with different alkyl chain lengths and monitor metabolic flux through the pathway.
Enzyme activity assays for PAF acetylhydrolases
PAF-AH activity is measured using radiolabeled or fluorescent PAF analogs, allowing kinetic characterization of PLA2G7, PAFAH1B2, and PAFAH1B3. These assays are essential for validating CRISPR knockout or point-mutation effects on enzyme function.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout or activation screens can identify novel regulators of PAF metabolism and PAF-induced phenotypes. Coupling screens with PAF-sensitive readouts, such as calcium flux or inflammatory cytokine release, enables discovery of pathway components.
Transcriptomics and proteomics
RNA-seq and proteomics can reveal expression changes in PAF metabolic genes under inflammatory or radiation conditions. These approaches help contextualize PAF metabolism within broader lipid mediator networks.
How CRISPR Can Be Used to Study GO:0046469 platelet activating factor metabolic process
Knockout
CRISPR knockout of PAF metabolic genes such as PLA2G7, PAFAH1B2, or LPCAT2 allows researchers to determine their contribution to PAF levels and downstream signaling. Knockout cell models can be used to measure changes in PAF half-life, inflammatory cytokine release, and response to radiation.
Point Mutation
Point mutations in catalytic residues of PAF acetylhydrolases or in the PAF receptor can dissect enzyme activity from scaffolding functions. For example, mutating the catalytic serine of PLA2G7 can abolish its hydrolase activity while preserving protein interactions.
Knock-in
Knock-in of tagged versions of PAF metabolic enzymes (e.g., GFP or HA tags) enables real-time tracking of localization and complex formation. Knock-in of disease-associated variants, such as PAFAH1B1 mutations, can model lissencephaly in neuronal cells.
Overexpression
Overexpression of PAF biosynthetic enzymes like LPCAT2 or PLA2G4A can increase PAF production and amplify inflammatory responses. Conversely, overexpression of PAF-AH enzymes can reduce PAF levels and protect against PAF-mediated injury.
How EDITGENE Supports platelet activating factor metabolic process Research
Researchers studying platelet activating factor metabolic process-related genes often need to determine whether a candidate gene is causally involved in PAF synthesis, degradation, or signaling. EDITGENE provides a comprehensive suite of CRISPR-based cell model services to enable these functional studies with high precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for platelet activating factor metabolic process research.
Frequently Asked Questions About platelet activating factor metabolic process
What is platelet activating factor metabolic process?
It is the set of chemical reactions that synthesize, remodel, and degrade platelet activating factor (PAF), a potent inflammatory phospholipid mediator, as defined by GO:0046469.
What genes are involved in platelet activating factor metabolic process?
Key genes include PLA2G7, PAFAH1B1, PAFAH1B2, PAFAH1B3, LPCAT1, LPCAT2, PLA2G4A, and PTAFR, among others.
What is the function of PAF acetylhydrolase?
PAF acetylhydrolases remove the sn-2 acetyl group from PAF, converting it to inactive lyso-PAF and terminating its signaling.
How is PAF synthesized in cells?
PAF is synthesized via the remodeling pathway, where PLA2G4A generates lyso-PAF and LPCAT1/2 acetylate it, or via the de novo pathway from 1-O-alkyl-2-acetyl-sn-glycerol.
What diseases are linked to PAF metabolism?
PAF metabolism is linked to atherosclerosis, cancer, neurodegeneration, asthma, and radiation-induced inflammation.
How can CRISPR be used to study PAF metabolism?
CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to test the causal role of PAF metabolic genes in cells and animal models.
What is the role of PLA2G7 in PAF metabolism?
PLA2G7 encodes plasma PAF acetylhydrolase, which degrades PAF and oxidized phospholipids and is a biomarker for cardiovascular risk.
Is PAF involved in cancer?
Yes, PAF signaling promotes cancer cell proliferation and survival, and radiation therapy can generate PAF agonists in tumors.
What is the PAF receptor?
The PAF receptor (PTAFR) is a G-protein-coupled receptor that mediates PAF-induced platelet aggregation, leukocyte activation, and vascular permeability.
How is PAF metabolism regulated?
PAF metabolism is regulated by transcriptional induction of biosynthetic enzymes, calcium-dependent translocation of phospholipases, and secretion of acetylhydrolases.
Conclusion
GO:0046469 platelet activating factor metabolic process is a tightly regulated pathway that controls the synthesis and degradation of one of the most potent lipid mediators of inflammation. The balance between biosynthetic enzymes such as LPCAT1/2 and PLA2G4A and degradative enzymes such as PLA2G7 and PAFAH1B2/3 determines PAF bioavailability and signaling duration. Dysregulation of this pathway contributes to atherosclerosis, cancer, neurodegeneration, and allergic diseases, making its components attractive therapeutic targets. CRISPR-based cell models provide powerful tools to dissect the causal roles of PAF metabolic genes and to identify novel intervention points. EDITGENE offers comprehensive services to accelerate this research.
References
- 1. Kono N et al.. 2019. Platelet-activating factor acetylhydrolases: An overview and update.. Biochim Biophys Acta Mol Cell Biol Lipids 1864(6):922-931 PMID: 30055287
- 2. Prescott SM et al.. 2000. Platelet-activating factor and related lipid mediators.. Annu Rev Biochem 69:419-45 PMID: 10966465
- 3. Chung KF. 1997. Platelet activating factor revisited.. Thorax 52(12):1019-20 PMID: 9516891
- 5. Sahu RP et al.. 2016. Radiation therapy generates platelet-activating factor agonists.. Oncotarget 7(15):20788-800 PMID: 26959112
- 6. Sirangelo I et al.. 2013. Amyloid toxicity and platelet-activating factor signaling.. J Cell Physiol 228(6):1143-8 PMID: 23169529
- 7. Tokumura A et al.. 2000. Platelet-activating factor (PAF)-like oxidized phospholipids: relevance to atherosclerosis.. Biofactors 13(1-4):29-33 PMID: 11237195
- 8. Frenkel RA et al.. 1992. Metabolic conversion of platelet-activating factor into ethanolamine plasmalogen in an amnion-derived cell line.. J Biol Chem 267(27):19186-91 PMID: 1527040
